Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management

Area of Science:

• Hematology
• Cardiology
• Oncology

Background:

• Allogeneic hematopoietic stem cell transplantation (HSCT) is increasingly performed worldwide, leading to a growing population of long-term survivors.
• Long-term survivors of HSCT are at risk for late effects, including therapy-related cardiovascular disease.
• Cardiovascular complications, particularly those linked to dyslipidemia, represent a significant cause of morbidity and mortality post-HSCT.

Purpose of the Study:

• To review the risks and causes of dyslipidemia following HSCT.
• To examine the impact of dyslipidemia on cardiovascular complications in HSCT survivors.
• To propose a management approach for dyslipidemia in the HSCT population due to the absence of established guidelines.

Main Methods:

• Literature review focusing on dyslipidemia and cardiovascular complications in allogeneic HSCT survivors.
• Analysis of factors influencing dyslipidemia management, including immunosuppressive therapy and chronic graft-versus-host disease.
• Synthesis of current knowledge to propose a clinical management strategy.

Main Results:

• Dyslipidemia is a prevalent complication after HSCT, contributing to premature cardiovascular events.
• Factors such as immunosuppressive agents and chronic graft-versus-host disease significantly impact lipid profiles and cardiovascular risk.
• There is a lack of specific guidelines for managing dyslipidemia in this patient population.

Conclusions:

• Dyslipidemia is a critical late effect of HSCT that necessitates proactive management to mitigate cardiovascular risks.
• A tailored approach considering HSCT-specific factors is required for effective dyslipidemia management in survivors.
• Further research and guideline development are needed to optimize cardiovascular care for HSCT recipients.